Atorvastatin 20 mg (n=25 lesions) Atorvastatin 5 mg (n=25 lesions)

Slides:

Advertisements

Similar presentations

Sibbing D, et al. J Am Coll Cardiol 2009;53:

Advertisements

Baseline Characteristics According to CET Rate Marianne Zeller, et al. J Am Coll Cardiol 2007;50:

Resistant hypertension increases patients’ cardiovascular risk 30% of all treated patients develop resistant hypertension [1-5]. Resistant hypertension.

Lindsay and Choudhury, Nature Reviews: Drug Discovery 2008, 7: Imaging the vessel wall in atherosclerosis.

S ystolic H eart failure treatment with the I f inhibitor ivabradine T rial Selective heart rate reduction with ivabradine unloads the left ventricle in.

Patient disposition Dichtl W, et al. Am J Cardiol. 2008;102:743-8 AVR = aortic valve replacement; MDCT = multidetector computed tomographic.

VBWG BRAVER Trial BRachial Artery Vascular Endothelium Reactivity Study A substudy of PROVE IT-TIMI 22.

Aortic and Carotid Magnetic Resonance Image (MRI) Imaging

Hsia J et al. J Am Coll Cardiol 2011;57: Baseline Characteristics by Treatment Group and Attained LDL-C Hsia J et al. J Am Coll Cardiol 2011;57:

ACE inhibitors, ARBs and Statins in COPD: High- and Low-Risk Cohorts G. B. John Mancini, et al. J Am Coll Cardiol 2006;47:

SONG XIANTAO MD Beijing Anzhen Hospital affiliated to Capital Medical University.

Date of download: 5/29/2016 Copyright © The American College of Cardiology. All rights reserved. From: Renal Denervation in Moderate Treatment-Resistant.

Date of download: 5/31/2016 Copyright © The American College of Cardiology. All rights reserved. From: Spectrum and prognostic significance of arrhythmias.

Date of download: 6/7/2016 Copyright © The American College of Cardiology. All rights reserved. From: Procedural and Mid-Term Results in Patients With.

Date of download: 6/22/2016 Copyright © The American College of Cardiology. All rights reserved. From: Inhibition of Vascular Oxidative Stress in Hypercholesterolemia.

The reading is 7.38 mm. The reading is 7.72 mm.

Impact of Triglyceride Levels Beyond Low-Density Lipoprotein Cholesterol After Acute Coronary Syndrome in the PROVE IT-TIMI 22 Trial Michael Miller MD,

Adapted from Weiss et al. J Am Coll Cardiol. 1998;31:

Treatment LDL-C: baseline (mg/dL) LDL-C: 24 mo (mg/dL) p

EARLY-BAMI Trial design: Patients presenting with STEMI with a plan for primary PCI, and without evidence of cardiogenic shock, were randomized to either.

Oxford Niacin Trial.

TNT: Baseline and final LDL cholesterol levels

Cholesterol and blood pressure values at baseline and after 15 days of dark-chocolate and white-chocolate consumption Characteristic Dark chocolate before.

TECAM Trial design: STEMI patients who underwent successful reperfusion therapy were randomized on day 1 to intracoronary bone marrow autologous mononuclear.

AARDVARK Trial design: Patients with small abdominal aortic aneuryms (AAAs) were randomized in a 1:1:1 fashion to either perindopril 10 mg once daily,

Change in mean LVMI with erythropoietin alpha hemoglobin maintenance treatment and control/delayed treatment from baseline to 24 months End point Hemoglobin.

Effect of evolocumab on lipoprotein particles

INOVATE-HF Trial design: Patients with heart failure (HF) were randomized to device implant for vagus nerve stimulation (n = 436) versus optimal medical.

Variable Pretreatment Posttreatment P GFR (mL/min) 115±18 102±14 NS

Losartan vs. Atenolol in Marfan Syndrome

POSEIDON-DCM Trial design: Patients with nonischemic dilated cardiomyopathy were randomized to transendocardial injection of allogenic (n = 18) vs. autologous.

Median total new lesion volume

PREMIER: Rate of hypertension at 18 months

TNT post hoc analysis: Improvement between baseline and final visit in estimated GFR by treatment group End point 10-mg atorvastatin 80-mg atorvastatin.

Figure 2 Imaging of atherosclerotic plaque burden

SMILE Trial design: NSTEMI patients were randomized to complete revascularization during the index procedure (i.e., 1-stage revascularization; n = 264)

EVERBIO II Trial design: Patients with CAD were randomized in a 1:1:1 fashion to either Absorb BVS, Biomatrix Flex stent [BES], or Promus Element EES.

Nat. Rev. Cardiol. doi: /nrcardio

Time point Difference in systolic BP (mm Hg) p

Axial source images of left severe ICA stenosis; small residual lumen with vessel wall plaque and thick calcification on the sides. Axial source images.

ZEUS Trial design: Patients who were deemed uncertain DES candidates due to bleeding, thrombotic, or restenosis risk were randomized to receive either.

Aortic angiosarcoma masquerading as a thoracic aortic aneurysm

TACTICS-HF Trial design: Patients with acute heart failure (reduced or preserved ejection fraction) were randomized to tolvaptan 30 mg at 0, 24, and 48.

AFACT Trial design: Patients with long-standing atrial fibrillation were randomized to ganglion plexus ablation (n = 117) vs. control (n = 123) on top.

BRAVO-3 Trial design: Patients undergoing transfemoral TAVR were randomized in a 1:1 fashion to bivalirudin or UFH. They were followed for 30 days. Results.

Role of Stenting in Acute MI: PAMI Stent Pilot Trial

Mancini JG, et al. Am J Cardiol.

Fig. 2 Elastic fiber fragmentation and SMC disarray in descending aorta of Fbln4E57K/E57K mice. Elastic fiber fragmentation and SMC disarray in descending.

Baseline Characteristics of Cardiovascular Risk Factors and Selected Dietary Variables in a Cohort of 22,881 Men and 35,091 Women to Quintile of Fish Intakes.

Clinical Characteristics and Atheroma Burden of Subjects at Baseline Stratified According to Gender Nicholls SJ. et al. J Am Coll Cardiol 2007;49:

Baseline Characteristics, Values at 24-Month Follow-up, and Changes from Baseline* - Part I John J.P. Kastelein, et al. N Engl J Med 2007;356: online.

A, Sagittal T1 MR imaging. A, Sagittal T1 MR imaging. Multiple bone lesions with T1 hyperintensity involve the cervical and thoracic spine, with a pathologic.

Maintenance of Long-Term Clinical Benefit with

Baseline Patients with coronary artery disease (CAD) and high (n=98) versus normal (n=1512) high-density lipoprotein (HDL) levels Doreen DeFaria Yeh, et.

Baseline Clinical Characteristics

Baseline Characteristics of Study Subjects

DENERHTN Trial design: Patients with resistant hypertension were randomized to renal denervation plus standardized stepped-care antihypertensive treatment.

Saurabh Kumar et al. JACEP 2017;3:

Change from baseline in the severity of morning cough and severity of difficulty bringing up phlegm in the morning over the study period in the active-comparator.

Circulatory system Quiz

IMPRESS Trial design: Patients undergoing primary PCI for STEMI and cardiogenic shock were randomized in a 1:1 to either Impella CP or IABP. They were.

Baseline characteristics of the 1,842 men without coronary heart disease and the 230 men with a first coronary heart disease event during the 13-year.

Baseline demographics and clinical characteristics of 3,956 rosuvastatin-treated patients Donald G. Vidt, et al. Am J Cardiol 2006;97:1602–1606.

Demographic Characteristics of Patients Treated With Statins Versus Those Not Treated With Statins Goldberger JJ, et al. J Am Coll Cardiol 2006;48:

Frankel DS, et al. J Am Coll Cardiol. 2009;53:754-62

Maximum intensity projection of a time-of-flight angiography (TR, 28 ms; TE, 4.92 ms; matrix, 704 × 576; FOV, 163 × 200 mm2; 92 sections; section thickness,

Distribution of patient baseline characteristics among included studies. Distribution of patient baseline characteristics among included studies. Each.

A left centrum semiovale lesion in a 30-year-old woman with relapsing-remitting MS; the time lapse between 3T and 7T scans was 6 months. A left centrum.

Average change in blood pressure (BP) from recruitment to 6-month postrecruitment in intervention and control patients >50 years included due to having.

Atrophied Brain T2 Lesion Volume at MRI Is Associated with Disability Progression and Conversion to Secondary Progressive Multiple Sclerosis The rate.

Presentation transcript:

Changes in vessel-wall thickness and vessel-wall area in the thoracic aorta Atorvastatin 20 mg (n=25 lesions) Atorvastatin 5 mg (n=25 lesions) p (20 mg vs 5 mg) Maximal vessel-wall thickness Baseline (mm) 3.8 3.7 NS 12 months (mm) 3.3 <0.05 Change (%) -12.0 +1.0 <0.001 p (compared with baseline) - Vessel-wall area Baseline (mm2) 135 12 months (mm2) 112 139 -18.0 +4.0 — Yonemura A et al. J Am Coll Cardiol 2005; 45:733-42.

Changes in vessel-wall thickness and vessel-wall area in the abdominal aorta Atorvastatin 20 mg (n=35 lesions) Atorvastatin 5 mg (n=40 lesions) p (20 mg vs 5 mg) Maximal vessel-wall thickness Baseline (mm) 3.3 3.2 NS 12 months (mm) Change (%) -1.0 +5.0 <0.02 p (compared with baseline) <0.01 — Vessel-wall area Baseline (mm2) 85 81 12 months (mm2) 87 89 +3.0 +12.0 <0.05 <0.001 Yonemura A et al. J Am Coll Cardiol 2005; 45:733-42.